Aerium Therapeutics

In year 3 of the pandemic, a new Covid-19 biotech takes flight with an antibody combo and Takeda's ex-vaccines chief at the helm
Endpoints
Tue, 03/22/22 - 10:12 am
COVID-19
Aerium Therapeutics
monoclonal antibodies
Omega Funds